Millie
your market intelligence analyst
Search Results
379 results
Your search is now limited to «Pancreatic Cancer» expert search.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide, associated with poor prognosis even when diagnosed at an early clinical stage (CS). Despite advances in surgery, radiotherapy, and chemotherapy, the 5-year overall survival rate is only 7.0-8.5% [1]. FOLFIRINOX (5-fluorouracil, irinotecan, and oxaliplatin) and nab-paclitaxel plus gemcitabine are first-line treatment options in the metastatic setting, with a median overall survival of less than 1 year [2,3].
Environmental News Network 09/18/2019 17:21
The work, described online in July in the journal Cancer Research, found that 4-HAP reduced metastatic tumor formation in a mouse model of human pancreatic cancer by assessing the fraction of liver surface covered by tumor tissue.
More from Environmental News Network:
News-Medical.net 09/18/2019 13:04
The group then tested 4-HAP as a treatment in a mouse model of pancreatic cancer, finding that the compound led to a 50% reduction in metastases to the liver in mice transplanted with human pancreatic tissue.
More from News-Medical.net:
Medical Xpress - Cancer News 09/18/2019 11:47
Study finds new way to make chemotherapy more effective against pancreatic cancer.
More from Medical Xpress - Cancer News:
To be eligible for a Translational Research Grant, the research project should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance.
More from Pancreatic Cancer Action Network:
Seeking Alpha 09/17/2019 10:15
However, the recent pancreatic cancer data has me reconsidering a potential buy as we closeout 2019.
More from Seeking Alpha:
GlobeNewswire 09/17/2019 09:00
Despite these outcomes, pancreatic cancer receives less than 2% of cancer research funding in the region, making it an essential location for us to open our Phase 3 clinical trial in metastatic pancreatic cancer.
More from GlobeNewswire:
ClinicalTrials.gov 09/17/2019 07:02
A statistical analysis of patient survival will be performed, comparing study participants to historical data from the Danish national database of pancreatic cancer patients.
More from ClinicalTrials.gov:
PubMed News (NIH) 09/17/2019
Pancreatic ductal adenocarcinoma (PDAC) is characterized by massive heterogeneity, with the coexistence at all disease stages of well- and poorly-differentiated cells with diverging transcriptional networks.
More from PubMed News (NIH):
FeedNavigator (EU) 09/13/2019 06:07
The poor survival of pancreatic cancer emphasizes the urgent need to identify the causes or the risk factors of pancreatic cancer in order to establish effective preventive strategies.
More from FeedNavigator (EU):
Metastasis is complex, involving multiple genetic, epigenetic, biochemical, and physical changes in the cancer cell and its microenvironment. Cells with metastatic potential are often characterized by altered cellular contractility and deformability, lending them the flexibility to disseminate and navigate through different microenvironments. We demonstrate that mechanoresponsiveness is a hallmark of pancreatic cancer cells. Key mechanoresponsive proteins, those that accumulate in response to mechanical stress, specifically nonmuscle myosin IIA (MYH9) and IIC (MYH14), α-actinin 4, and filamin B, were highly expressed in pancreatic cancer as compared with healthy ductal epithelia. Their less responsive sister paralogs—myosin IIB (MYH10), α-a.
More from Cancer Research - Recent Issues (abstracts):
Purpose:. Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that is broadly chemoresistant, due in part to biophysical properties of tumor stroma, which serves as a barrier to drug delivery for most classical chemotherapeutic drugs. The goal of this work is to evaluate the preclinical efficacy and mechanisms of PTC596, a novel agent with potent anticancer properties in vitro and desirable pharmacologic properties in vivo . Experimental Design: We assessed the pharmacology, mechanism, and preclinical efficacy of PTC596 in combination with standards of care, using multiple preclinical models of PDA. Results:. We found that PTC596 has pharmacologic properties that overcome the barrier to drug delivery in PDA, including a long circulating.
More from Clinical Cancer Research - Recent Issues (abstracts):
PR Newswire 09/12/2019 14:40
The walk, now in its eleventh year, has raised more than $820,000 for pancreatic cancer research since inception.
More from PR Newswire:
Pancreatic Cancer Action 09/12/2019 08:45
Pancreatic Cancer Action is calling for specific policy targets for pancreatic cancer as s urvival rates for the disease are particularly poor.
More from Pancreatic Cancer Action:
Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas.
More from Cell Communication & Signaling:
Technology Org 09/10/2019 06:30
This tactic is called “developing resistance,” and it’s one of the key challenges researchers face when seeking effective therapeutics to combat pancreatic ductal adenocarcinoma (PDA.
More from Technology Org:
Targeted Oncology 09/09/2019 10:48
Since the pancreas is a difficult-to-access organ, ideally we wanted to modulate the tumor microbiome.
More from Targeted Oncology:
FierceMedicalDevices 09/09/2019 10:24
The company discussed the results of the phase 2 trial at the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer in Boston.
More from FierceMedicalDevices:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications